Brief: Avacta Therapeutics Says FAP-Dox Initial Data In Salivary Gland Cancer Expected Late 2025
06/06/2025 07:28
June 6 (Reuters) - Avacta Group PLC AVCT.L: AVACTA THERAPEUTICS: FOR FAP-DOX (AVA6000) INITIAL DATA IN SALIVARY GLAND CANCER EXPECTED LATE 2025 & TRIPLE NEGATIVE BREAST CANCER H1 2026 AVACTA THERAPEUTICS: FAP-EXD (AVA6103) TO ENTER CLINICAL TESTING WITH IND FILING IN LATE 2025 & PHASE 1 TRIAL START IN H1 2026 AVACTA THERAPEUTICS: AS OF APRIL 30, 2025, £17.3 MILLION AFTER DIVESTMENT OF LAUNCH DIAGNOSTICS EXTENDING CO'S CASH RUNWAY INTO Q1 2026 Source text: ID:nRSF7780La Further company coverage: AVCT.L ((Reuters.Briefs@thomsonreuters.com))